Cargando…

β‐Hydroxyisovalerylshikonin Is a Novel and Potent Inhibitor of Protein Tyrosine Kinases

β‐Hydroxyisovalerylshikonin (β‐HIVS), a compound isolated from Lithospermium radix, most efficiently induced cell‐death in two lines of lung cancer cells, namely, NCI‐H522 and DMS114, whereas shikonin was effective against a wide variety of tumor cell lines. During our studies of the mechanism of ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hashimoto, Sachiko, Xu, Ying, Masuda, Yutaka, Aiuchi, Toshihiro, Nakajo, Shigeo, Uehara, Yoshimasa, Shibuya, Masabumi, Yamori, Takao, Nakaya, Kazuyasu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2002
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927115/ https://www.ncbi.nlm.nih.gov/pubmed/12716473 http://dx.doi.org/10.1111/j.1349-7006.2002.tb01341.x

Ejemplares similares

Selective Inhibitory Effect of Bufalin on Growth of Human Tumor Cells in vitro: Association with the Induction of Apoptosis in Leukemia HL‐60 Cells
por: Jing, Yongkui, et al.
Publicado: (1994)

Characterization of the Extracellular Domain in Vascular Endothelial Growth Factor Receptor‐1 (Flt‐1 Tyrosine Kinase)
por: Tanaka, Keiji, et al.
Publicado: (1997)

β-Hydroxyisovalerylshikonin regulates macrophage polarization via the AMPK/Nrf2 pathway and ameliorates sepsis in mice
por: Pan, Tao, et al.
Publicado: (2022)

Up‐regulation of p27(Kip1) Correlates Inversely with Anchorage‐independent Growth of Human Cancer Cell Lines
por: Kawada, Manabu, et al.
Publicado: (1998)

Topoisomerase Inhibitors Have Potent Differentiation‐inducing Activity for Human and Mouse Myeloid Leukemia Cells
por: Nakaya, Kazuyasu, et al.
Publicado: (1991)

Clotrimazole, an Imidazole Antimycotic, Is a Potent Inhibitor of Angiogenesis
por: Takahashi, Hiroto, et al.
Publicado: (1998)

Novel Anthraquinone-based Derivatives as Potent Inhibitors for Receptor Tyrosine Kinases
por: Stasevych, M., et al.
Publicado: (2015)

Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum
por: Nava, Maria G., et al.
Publicado: (2022)

Establishment of a Human Small Cell Lung Carcinoma Cell Line Carrying Amplification of c‐myc Gene and Chromosomal Translocation of t(3p;6p) and t(12q;17p)
por: Kato, Atsushi, et al.
Publicado: (1993)

Proteomic analysis of phosphoproteins sensitive to a phosphatidylinositol 3-kinase inhibitor, ZSTK474, by using SELDI-TOF MS
por: Akashi, Tetsuyuki, et al.
Publicado: (2009)

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2013)

Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
por: Furuto, Yoshitaka, et al.
Publicado: (2018)

Anti‐tumor Efficacy of Paclitaxel against Human Lung Cancer Xenografts
por: Yamori, Takao, et al.
Publicado: (1997)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2014)

Identification of a Novel Series of Potent TrkA Receptor Tyrosine Kinase Inhibitors
por: Raeppel, Stéphane L., et al.
Publicado: (2012)

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
por: Halbach, Sebastian, et al.
Publicado: (2016)

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties
por: Wang, Xiaojing, et al.
Publicado: (2017)

Co‐amplification of c‐myc and c‐erbB‐2 Oncogenes in a Poorly Differentiated Human Gastric Cancer
por: Tsuchiya, Terumasa, et al.
Publicado: (1989)

Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors
por: Ohashi, Yoshimi, et al.
Publicado: (2017)

Angiomyomatous hamartoma of the inguinal lymph nodes with localized lymphedema presenting as a soft subcutaneous mass
por: Honda, Ryoma, et al.
Publicado: (2022)

Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia
por: SHIBUYA, Masabumi
Publicado: (2011)

VEGF-VEGFR Signals in Health and Disease
por: Shibuya, Masabumi
Publicado: (2014)

Protein tyrosine kinase Abl promotes hepatitis C virus particle assembly via interaction with viral substrate activator NS5A
por: Miyamoto, Daisuke, et al.
Publicado: (2022)

Tyrosine Kinase Signaling in Kidney Glomerular Podocytes
por: Hattori, Seisuke, et al.
Publicado: (2011)

Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton’s Tyrosine Kinase Inhibitor
por: Lee, Keun Woo, et al.
Publicado: (2020)

New, potent, small molecule agonists of tyrosine kinase receptors attenuate dry eye disease
por: Yu, Zhiyuan, et al.
Publicado: (2022)

Sulfonylated Indeno[1,2-c]quinoline Derivatives as Potent EGFR Tyrosine Kinase Inhibitors
por: Hengphasatporn, Kowit, et al.
Publicado: (2023)

Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis
por: Nakade, Issei, et al.
Publicado: (2023)

Inhibitory Activity of Flavonoids against Class I Phosphatidylinositol 3-Kinase Isoforms
por: Kong, Dexin, et al.
Publicado: (2011)

Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase
por: Lee, Eun, et al.
Publicado: (2020)

Bioactive Phytoconstituents as Potent Inhibitors of Tyrosine-Protein Kinase Yes (YES1): Implications in Anticancer Therapeutics
por: Yang, Chunmin, et al.
Publicado: (2022)

Vascular Endothelial Growth Factor Receptor Family in Ascidians, Halocynthia roretzi (Sea Squirt). Its High Expression in Circulatory System-Containing Tissues
por: Samarghandian, Saeed, et al.
Publicado: (2013)

Targeting cancer cells resistant to hypoxia and nutrient starvation to improve anti-angiogeneic therapy
por: Osawa, Tsuyoshi, et al.
Publicado: (2013)

Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells
por: Vouri, Mikaella, et al.
Publicado: (2015)

Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening
por: Myers, Samuel H., et al.
Publicado: (2018)

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
por: Catlett, Ian M., et al.
Publicado: (2022)

Tyrosine Kinases in Cancer
por: Blau, Olga, et al.
Publicado: (2015)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
por: Liang, Chris, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_glujeiv12t95ia3j90dmejq6i7